, Volume 33, Issue 3, pp 407-412

Clinical significance of α1-adrenoceptor selectivity in the management of benign prostatic hyperplasia

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Alpha1-adrenoceptor antagonists have beenshown to provide effective relief from symptomsof benign prostatic hyperplasia (BPH) withattendant improvements in quality of life.Although the α1A-adrenoceptorsubtype predominates over other subtypes ofα1 adrenoceptors in the prostategland, there is no evidence that a subselectiveα-adrenoceptor antagonist provides aclinical advantage over a selectiveα1-adrenoceptor antagonist in thetreatment of patients with BPH. Thepharmacokinetic profiles ofα1A-adrenoceptorantagonists and their documented penetration ofthe blood-brain barrier (CNS adverse effects)preclude a clinical benefit of subselectiveα-adrenoceptor blockers over selectiveα1 blockers.